In this supplement text to EMJ Neurology, two key opinion leaders, Mark S Freedman and Lluís Ramió-Torrentà, discussed the current approaches and challenges in the assessment of disease activity and progression in relapsing-remitting multiple sclerosis (RRMS). The interviewees also provide their perspectives on this topic of disease activity and progression in patients with RRMS, including an overview of the measurement tools that can be utilised in clinical practice.
EMJ Neurology 9 [Supplement 2] . 2021
October 2021
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given